These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16803430)

  • 1. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?
    Krantz MJ
    Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430
    [No Abstract]   [Full Text] [Related]  

  • 2. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Type 2 diabetic as cardiovascular risk patient].
    Krankenpfl J; 2005; 43(4-6):106. PubMed ID: 16171052
    [No Abstract]   [Full Text] [Related]  

  • 4. [World news in age-related diabetes: blood sugar lowering can improve prognosis].
    Einecke D
    MMW Fortschr Med; 2005 Sep; 147(38):1. PubMed ID: 16218218
    [No Abstract]   [Full Text] [Related]  

  • 5. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 6. [Too positive comment on glitazones].
    Lindberg M
    Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract]   [Full Text] [Related]  

  • 7. [Glitazone - mailing no 1. In response to DMW 49/2007].
    Traut V
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
    [No Abstract]   [Full Text] [Related]  

  • 8. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 9. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
    Szymborska-Kajanek A; Strojek K
    Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
    [No Abstract]   [Full Text] [Related]  

  • 10. PROactive Study: (r)evolution in the therapy of diabetes?
    Ceriello A
    Diabet Med; 2005 Nov; 22(11):1463-4. PubMed ID: 16241907
    [No Abstract]   [Full Text] [Related]  

  • 11. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
    Schatz H
    Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1825-30. PubMed ID: 16052448
    [No Abstract]   [Full Text] [Related]  

  • 14. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
    MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
    [No Abstract]   [Full Text] [Related]  

  • 15. [Glitazone - mailing no 3. In response to DMW 49/2007].
    Gundel UF
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
    [No Abstract]   [Full Text] [Related]  

  • 16. [The effects of thiazolidinedione from the cardiologic viewpoint].
    Ziegler R
    Med Monatsschr Pharm; 2005 Oct; 28(10):365. PubMed ID: 16245456
    [No Abstract]   [Full Text] [Related]  

  • 17. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
    Vaccaro O; Riccardi G
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
    Donnelly R
    Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.